https://www.neurologylive.com/view/uniqure-receives-dsmb-recommendation-resume-higher-dosing-amt-130-huntington-trial
0
0
11/13/22 at 8:02pm
Organization
Neurologylive.com
Author
Marco Meglio
The 26-patient trial includes 10 individuals with early-manifest Huntington disease on low-dose AMT-130 and 16 in the high-dose cohort, which will continue enrollment after a DSMB found no further safety concerns.
Create an account
or login to join the discussion